International Commission for the Protection of the Environment against Mutagens and Carcinogens: A historical perspective

Mutation Research - Reviews in Mutation Research

Volumn 511, Issue 1, 2002, Pages 63-71

  Lohman, P H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; MUTAGENIC AGENT;

BIOLOGICAL MONITORING; CARCINOGENICITY; CONTROL STRATEGY; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL PROTECTION; GENETIC DISORDER; GENETIC SCREENING; GENOTOXICITY; HUMAN; MUTAGEN TESTING; MUTAGENICITY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0036130821     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(02)00002-9     Document Type: Review

References (115)

1. Chemical production of mutations
2. Some thoughts on the evaluations of environmental mutagens
3. Advice on screening of chemicals for mutagenicity
4. Genetic monitoring of human populations accidentally exposed to a suspected mutagenic chemical
5. The unique role of rodents in the detection of possible human carcinogens and mutagens
6. Screening strategy for chemicals that are potential germ-cell mutagens in mammals
7. Comparison between in vitro and in vivo tests for carcinogenicity
8. The role of metabolism in chemical mutagenesis and chemical carcinogenesis
9. Carcinogens and carcinogenesis enhancers
10. Critical assessment of the value of in vitro cell transformation for predicting in vivo carcinogenicity of chemicals
11. Mutagenesis in mammalian cells
12. Bacterial systems for carcinogenicity testing
13. An evaluation of assay procedures for detection of tumor promotors
14. An appraisal of predictive tests for carcinogenicity
15. International Commission for Protection against Environmental Mutagens and Carcinogens: Committee 2 Final Report. Mutagenesis testing as an approach to carcinogenesis
16. Regulatory approaches to the control of environmental mutagens and carcinogens
17. Sensitivity of various germ-cell stages to environmental mutagens
18. Extrapolation from species to species and from various cell-types in assessing risks from chemical mutagens
19. Polygenic effects and genetic changes affecting quantitative traits
20. Estimation of genetic risks and increased incidence of genetic disease due to environmental mutagens
21. Comparison of types of chemically-induced genetic changes in mammals
22. Perspectives in mutation epidemiolog. Part 1. Incidence and prevalence of genetic disease (excluding chromosomal aberrations) in human populations
23. Perspectives in mutation epidemiology. Part 2. Epidemiologic and design aspects of studies of somatic chromosome breakage and sister-chromatid exchange
24. Perspectives in mutation epidemiology. Part 3. Contribution of chromosome abnormalities to human morbidity and mortality and some comments upon surveillance of chromosome mutation rates
25. Perspectives in mutation epidemiology. Part 4. General principles and considerations
26. Perspectives in mutation epidemiology. Part 5. Modern medical practice versus environmental mutagens: Their possible dysgenic impact
27. Mutation epidemiology: Review and recommendations, A report to the International Commission for Protection against Environmental Mutagens and Carcinogens by Committee 5 (Epidemiology)
28. Perspectives in mutation epidemiology. Part 6. A 1983 view of sentinel phenotypes
29. Cigarette smoking: Does it carry a genetic risk?
30. An evaluation of the genetic toxicity of dichlorvos
31. Epidemiological studies of the possible carcinogenicity of hair dyes
32. An evaluation of the genetic toxicity of epichlorohydrin
33. Mutagenicity and teratogenicity of vinyl chloride monomer (VCM): Epidemiological evidence
34. Do treatments available for psoriasis patients carry a genetic or carcinogenic risk?
35. Isoniazid: An attempt at retrospective prediction
36. Dosimetry of genotoxic agents and dose-response relationships of their effects
37. Review of the evidence for the presence or absence of thresholds in the induction of genetic effects by genotoxic chemicals
38. Review of the genotoxicity and carcinogenicity of anti-schistosomal drugs: Is there a case for a study of mutation epidemiology?
39. Conclusions on the genotoxicity of alcohol and recommendations for further work
40. Genetic effects of ethanol
41. Metabolism and metabolic effects of ethanol, including interaction with drugs, carcinogens and nutrition
42. Alcohol as a mutagenic agent: Report of an ICPEMC expert group
43. Human acetaldehyde levels: Aspects of current interest
44. Genetic aspects of the relation between alcohol metabolism and consumption in humans
45. Acute aldehyde syndrome and chronic aldehydism
46. Effect of ethanol on nitrosamine metabolism and distribution: Implications for the role of nitrosamines in human cancer and for the influence of alcohol consumption on cancer incidence
47. Reproductive consequences of alcohol abuse: Males and females compared and contrasted
48. Inhibitors of mutagenesis and their relevance to carcinogenesis
49. The concept of negativity in experimental carcinogenesis
50. The International Commission for Protection against Environmental Mutagens and Carcinogens (ICPEMC): The first 7 years
51. Differentiation between genotoxic and non-genotoxic carcinogens
52. Diet, mutation and cancer
53. The need for biological risk assessment in reaching decisions about carcinogens
54. Can a mechanistic rationale be provided for non-genotoxic carcinogens identified in rodent bioassays?
55. The classification of carcinogens identified in the rodent bioassay as potential risks to humans: What type of substance should be tested next?
56. Oxidative DNA damage: The effects of certain genotoxic and operationally non-genotoxic carcinogens
57. Workshop on ataxia-telangiectasia heterozygotes and cancer
58. Genotoxicity under extreme culture conditions
59. Effects of dietary constituents on carcinogenesis in different tumor models: An overview from 1975 to 1988, Cancer and Nutrition, Plenum Press, New York
60. Recommendations for screening for potential human germ-cell mutagens: An ICPEMC working paper
61. Considerations for population monitoring using cytogenetic techniques
62. Testing for mutagens and carcinogens: The role of short-term genotoxicity assays: A report prepared by ICPEMC
63. The assembly and analysis of short-term genotoxicity test data: An ICPEMC Committee 1 working paper
64. A multi-factor ranking scheme for comparing the carcinogenic activity of chemicals
65. A method for combining and comparing short-term genotoxicity test data: Preface
66. A method for combining and comparing short-term genotoxicity test data: The basic system
67. A method for combining and comparing short-term genotoxicity test data: The optimal use of dose information
68. A method for combining and comparing short-term genotoxicity test data: Results and interpretation
69. ICPEMC Perspectives on the scientific basis of risk assessment in genetic toxicology
70. Is the incidence of Down syndrome increasing?
71. Mutation surveillance of sentinel anomalies in Hungary 1980-1984
72. A new approach to germinal mutation surveillance: Pair-wise evaluation of component elements in unidentified multiple congenital abnormalities
73. Banbury report no. 34
74. Intrauterine growth retardation as a potential endpoint in mutation epidemiology
75. Heterozygous effects of multi-locus deletions
76. Are somatic mutations involved in atherosclerosis
77. The possible involvement of somatic mutations in the development of atherosclerotic plaques, conclusions and recommendations
78. The possible involvement of somatic mutations in the development of atherosclerotic plaques
79. Mutational events in the etiology of arteriosclerotic plaques
80. Shared risk factors for cancer and atherosclerosis: A review of the epidemiological evidence
81. Animal studies suggesting involvement of mutagen/carcinogen exposure in atherosclerosis
82. The use of recombinant DNA technology to study gene alteration
83. Approaches to determining mutation rates in human DNA
84. Banbury report no. 30
85. Hazard identification
86. Assessment of exposures to genotoxic substances
87. Methods for dose and effect assessment
88. Risk characterization strategies for genotoxic environmental agents
89. Monitoring environmental genotoxicants
90. Power frequency electric and magnetic fields: A review of genetic toxicology
91. Spontaneous mutation and its place in risk assessment for chemical mutagens. Report of an ICPEMC Committee
92. Spontaneous mutation: Some conceptual difficulties
93. Spontaneous mutations in mammalian cells
94. Somatic mutation frequency, mutation rates and mutational spectra in the human population in vivo
95. Spontaneous mutations in germ-cells of the mouse: Estimates of mutation frequencies and a molecular characterization of mutagenic events
96. Impact of the molecular spectrum of mutational lesions on estimates of germinal gene mutation rates
97. Estimation of genetic risks of exposure to chemical mutagens: Relevance of data on spontaneous mutations and of experience with ionizing radiation
98. Two million rodent carcinogens? The role of SAR and QSAR in their detection
99. The subtlety of alkylating agents
100. Approaches to SAR in carcinogenesis and mutagenesis
101. Use of SAR in computer-assisted prediction of carcinogenicity and mutagenicity of chemicals by the TOPKAT program
102. The importance of the hydrophobic interaction in the mutagenicity of organic compounds
103. Structural implications of the ICPEMC method for quantifying genotoxicty data
104. Application of SAR methods to non-congeneric data bases associated with carcinogenicity and mutagenicity: Issues and approaches
105. Recombination and gene conversion
106. Cyclosporine A: Review of the genotoxicity and potential for adverse human reproductive and developmental effects
107. Genetic risk extrapolation from animal data to human disease: A taskgroup report of the International Commission for Protection Against Environmental Mutagens and Carcinogens (ICPEMC)
108. Mutagenicity and carcinogenicity of topoisomerase interactive agents
109. Deoxyribonucleoside triphosphate levels: A critical factor in the maintenance of genetic stability
110. An evaluation of the genetic toxicity of paracetamol
111. Qualitative and quantitative procedures for health risk assessment
112. How we should deal with unavoidable exposure of man to environmental mutagens: Cooked food mutagen discovery, facts and lessons for cancer prevention
113. Toxicology and genetic toxicology in the new era of toxicogenomics: Impact of "-omics" Technologies
114. Molecular epidemiology and cancer: Promising areas for future research in the post-genomic era